Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Axelsson

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Immunology|August 29, 2022
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosisIgal Rosenstein, Sofia Rasch, Markus Axelsson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2013
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosisMarkus Axelsson, Clas Malmeström, Martin Gunnarsson, et al.
Multiple Sclerosis and Related Disorders|April 2, 2026
Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosisMagnus Johnsson, Jan Lycke, Lenka Novakova, et al.
Annals of Clinical and Translational Neurology|June 17, 2022
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorderMagnus Johnsson, Fredrik Asztely, Susanne Hejnebo, et al.
Acta Neurologica Scandinavica|January 19, 2019
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapiesMarkus Axelsson, Nicolas Dubuisson, Lenka Novakova, et al.
Journal of Neurology|April 26, 2024
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosisIgal Rosenstein, Anna Nordin, Hemin Sabir, et al.
Frontiers in Neurology|October 9, 2023
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosisSofia Sandgren, Lenka Novakova, Anna Nordin, et al.
Journal of Neurology|June 14, 2023
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosisIgal Rosenstein, Markus Axelsson, Lenka Novakova, et al.
Perfusion|November 7, 2023
A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusionAnna Corderfeldt Keiller, Markus Axelsson, Gudrun Bragadottir, et al.
Frontiers in Immunology|February 6, 2023
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosisIgal Rosenstein, Markus Axelsson, Lenka Novakova, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Immunology|August 29, 2022
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosisIgal Rosenstein, Sofia Rasch, Markus Axelsson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2013
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosisMarkus Axelsson, Clas Malmeström, Martin Gunnarsson, et al.
Multiple Sclerosis and Related Disorders|April 2, 2026
Calprotectin reveals distinct innate immune signatures in NMOSD, MOGAD, and multiple sclerosisMagnus Johnsson, Jan Lycke, Lenka Novakova, et al.
Annals of Clinical and Translational Neurology|June 17, 2022
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorderMagnus Johnsson, Fredrik Asztely, Susanne Hejnebo, et al.
Acta Neurologica Scandinavica|January 19, 2019
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapiesMarkus Axelsson, Nicolas Dubuisson, Lenka Novakova, et al.
Journal of Neurology|April 26, 2024
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosisIgal Rosenstein, Anna Nordin, Hemin Sabir, et al.
Frontiers in Neurology|October 9, 2023
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosisSofia Sandgren, Lenka Novakova, Anna Nordin, et al.
Journal of Neurology|June 14, 2023
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosisIgal Rosenstein, Markus Axelsson, Lenka Novakova, et al.
Perfusion|November 7, 2023
A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusionAnna Corderfeldt Keiller, Markus Axelsson, Gudrun Bragadottir, et al.
Frontiers in Immunology|February 6, 2023
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosisIgal Rosenstein, Markus Axelsson, Lenka Novakova, et al.
Pageof 9